Grant: Collaborative Health Research Projects
University of Alberta
$65,614.00
Nanosystems in transplantation: blood group antigens as immunologic tolerogens for infant heart transplantation
FY 2008-09
Summary
Nanosystems in Transplantation:
Blood group antigens as immunologic tolerogens for infant heart transplantation
In heart transplantation, blood group matching between donor and recipient is necessary to prevent a rapid form of rejection called 'hyperacute' rejection, which results in loss of the transplant or patient death. Recent studies showed, however, that blood group mismatched heart transplants are possible when performed in infancy. The success of these transplants lies in the normal lag in development of certain antibodies in infants. Thus, during infancy, absence of ABO-antibodies allows safe heart transplantation from a mismatched donor. Furthermore, the mismatched transplant does not provoke new antibodies to be formed; indeed, the foreign blood group substances on the transplanted heart were shown to induce a state of'tolerance', which actually prevents development of these antibodies as the infant grows into childhood. Despite these successes, the availability of donor organs for infants is particularly low. Increasing the length of this immunological 'grace period' would allow transplants to be performed at an older age when donor organs may be more readily available. The goal of this project is to test the ability of artificial blood group substances to induce tolerance during immaturity in a similar manner as mismatched heart transplants. If successful, this would lead to a lengthening of the window during which blood group mismatched heart transplants can be performed safely, allowing more children to be transplanted. This project is collaboration between Prof. Lori West, UofA Dept. of Pediatrics, Director of Heart Transplant Research, Faculty of Medicine and Dentistry, Prof. Todd Lowary, UofA Dept. of Chemistry/Alberta Ingenuity Centre for Carbohydrate Science, and Prof. Jillian Buriak, UofA Dept. of Chemistry/NRC National Institute of Nanotechnology. This is an exciting and entirely novel multidisciplinary project with enormous clinical potential, which combines the expertise of diverse areas of research in chemistry and medicine.
Program
Collaborative Health Research Projects
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
350946-2008
Name nom
West, Lori
Department département
Pediatrics
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
65614
Program id
CHRPJ
Program nane en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
3
Application title
Nanosystems in transplantation: blood group antigens as immunologic tolerogens for infant heart transplantation
Keyword
NA
Application summary
Nanosystems in Transplantation:
Blood group antigens as immunologic tolerogens for infant heart transplantation
In heart transplantation, blood group matching between donor and recipient is necessary to prevent a rapid form of rejection called 'hyperacute' rejection, which results in loss of the transplant or patient death. Recent studies showed, however, that blood group mismatched heart transplants are possible when performed in infancy. The success of these transplants lies in the normal lag in development of certain antibodies in infants. Thus, during infancy, absence of ABO-antibodies allows safe heart transplantation from a mismatched donor. Furthermore, the mismatched transplant does not provoke new antibodies to be formed; indeed, the foreign blood group substances on the transplanted heart were shown to induce a state of'tolerance', which actually prevents development of these antibodies as the infant grows into childhood. Despite these successes, the availability of donor organs for infants is particularly low. Increasing the length of this immunological 'grace period' would allow transplants to be performed at an older age when donor organs may be more readily available. The goal of this project is to test the ability of artificial blood group substances to induce tolerance during immaturity in a similar manner as mismatched heart transplants. If successful, this would lead to a lengthening of the window during which blood group mismatched heart transplants can be performed safely, allowing more children to be transplanted. This project is collaboration between Prof. Lori West, UofA Dept. of Pediatrics, Director of Heart Transplant Research, Faculty of Medicine and Dentistry, Prof. Todd Lowary, UofA Dept. of Chemistry/Alberta Ingenuity Centre for Carbohydrate Science, and Prof. Jillian Buriak, UofA Dept. of Chemistry/NRC National Institute of Nanotechnology. This is an exciting and entirely novel multidisciplinary project with enormous clinical potential, which combines the expertise of diverse areas of research in chemistry and medicine.